GlassScriptPhysician profile
Elliot L Naidus
NPI 1760821979
$3,743.85
in general payments reported to CMS, 2019-2025
18 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $111 · 2021: $130 · 2022: $139 · 2023: $138 · 2024: $2,874 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $760.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,595.80 | 2021-2024 | |
| Glaxosmithkline, LLC. | $357.59 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Inari Medical, INC. | $176.87 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.32 | 2023-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $82.94 | 2019-2025 | Airsupra, Breztri |
| Baxter Healthcare | $59.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Erbe USA INC | $47.00 | 2024-2025 | Cryo2 |
| Pulmonx Corporation | $44.27 | 2020 | |
| Merck Sharp & Dohme LLC | $43.88 | 2023-2024 | Pneumovax 23, Vaxneuvance, Zerbaxa |
| Insmed, INC. | $40.98 | 2019-2020 | |
| Amgen INC. | $30.23 | 2025 | Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $30.03 | 2022 | |
| United Therapeutics Corporation | $28.63 | 2024 | Tyvaso |
| Lilly USA, LLC | $26.81 | 2025 | Zepbound, Mounjaro |
| Mayne Pharma Commercial LLC | $22.82 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $22.24 | 2019 | |
| Resmed Corp | $21.75 | 2019 | |
| Genzyme Corporation | $18.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Naidus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.